These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21606452)

  • 21. Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
    Castela I; Casado-Polanco R; Rubio YV; da Silva JA; Marquez R; Pro B; Moratalla R; Redgrave P; Costa RM; Obeso J; Hernandez LF
    Neurobiol Dis; 2023 Jan; 176():105930. PubMed ID: 36414182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin 5-HT
    Pinna A; Parekh P; Morelli M
    Neuropharmacology; 2023 Mar; 226():109411. PubMed ID: 36608814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
    Pagano G; Yousaf T; Politis M
    Curr Neurol Neurosci Rep; 2017 Oct; 17(11):90. PubMed ID: 28975571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
    Calon F; Birdi S; Rajput AH; Hornykiewicz O; Bédard PJ; Di Paolo T
    J Neuropathol Exp Neurol; 2002 Feb; 61(2):186-96. PubMed ID: 11853020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological interactions between adenosine A
    Pinna A; Serra M; Marongiu J; Morelli M
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
    Chase TN; Bibbiani F; Bara-Jimenez W; Dimitrova T; Oh-Lee JD
    Neurology; 2003 Dec; 61(11 Suppl 6):S107-11. PubMed ID: 14663022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
    Wang L; Wang M; Si Q; Yuan Y; Ma K; Gan C; Zhang K
    Parkinsonism Relat Disord; 2019 Oct; 67():36-41. PubMed ID: 31621605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
    Paton DM
    Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting adenosine A2A receptors in Parkinson's disease.
    Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
    Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenosine A
    Marques TR; Natesan S; Rabiner EA; Searle GE; Gunn R; Howes OD; Kapur S
    Psychopharmacology (Berl); 2022 Nov; 239(11):3439-3445. PubMed ID: 34175983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How do adenosine A
    Mori A
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect.
    Mihara T; Noda A; Arai H; Mihara K; Iwashita A; Murakami Y; Matsuya T; Miyoshi S; Nishimura S; Matsuoka N
    J Nucl Med; 2008 Jul; 49(7):1183-8. PubMed ID: 18552135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of an Adenosine A
    Prasad K; de Vries EFJ; Sijbesma JWA; Garcia-Varela L; Vazquez-Matias DA; Moraga-Amaro R; Willemsen ATM; Dierckx RAJO; van Waarde A
    Mol Pharm; 2022 Aug; 19(8):2992-3001. PubMed ID: 35849844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.